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Structural features distinguishing 
infectious ex vivo mammalian 
prions from non-infectious fibrillar 
assemblies generated in vitro
Cassandra Terry1,5, Robert L. Harniman2, Jessica Sells1,6, Adam Wenborn1, Susan Joiner1, 
Helen R. Saibil3, Mervyn J. Miles4, John Collinge1 & Jonathan D. F. Wadsworth  1
Seeded polymerisation of proteins forming amyloid fibres and their spread in tissues has been 
implicated in the pathogenesis of multiple neurodegenerative diseases: so called “prion-like” 
mechanisms. While ex vivo mammalian prions, composed of multichain assemblies of misfolded 
host-encoded prion protein (PrP), act as lethal infectious agents, PrP amyloid fibrils produced in 
vitro generally do not. The high-resolution structure of authentic infectious prions and the structural 
basis of prion strain diversity remain unknown. Here we use cryo-electron microscopy and atomic 
force microscopy to examine the structure of highly infectious PrP rods isolated from mouse brain in 
comparison to non-infectious recombinant PrP fibrils generated in vitro. Non-infectious recombinant 
PrP fibrils are 10 nm wide single fibres, with a double helical repeating substructure displaying small 
variations in adhesive force interactions across their width. In contrast, infectious PrP rods are 20 nm 
wide and contain two fibres, each with a double helical repeating substructure, separated by a central 
gap of 8–10 nm in width. This gap contains an irregularly structured material whose adhesive force 
properties are strikingly different to that of the fibres, suggestive of a distinct composition. The 
structure of the infectious PrP rods, which cause lethal neurodegeneration, readily differentiates them 
from all other protein assemblies so far characterised in other neurodegenerative diseases.
Mammalian prions are infectious agents composed principally or entirely of multichain assemblies of misfolded, 
host-encoded prion protein (a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein), some of 
which acquire protease-resistance and are classically designated as PrPSc 1–3. Prions propagate by means of seeded 
protein polymerization, a process that involves the recruitment of PrP monomers to fibrillar assemblies followed 
by fission of the polymer to produce more “seeds”. Different prion strains can propagate in the same inbred host 
to produce different disease phenotypes and appear to be encoded by distinct PrP conformations and assembly 
states1–3. It is now clear that elucidating the molecular processes involved in mammalian prion propagation and 
strain diversity will be of major relevance to understanding other human neurodegenerative diseases (including 
Alzheimer’s and Parkinson’s disease) where seeded polymerisation or “prion-like” propagation of other protein 
assemblies is now a major research focus3–7. To date, despite enormous international effort, the high resolution 
structure of an infectious mammalian prion remains unknown. Consequently, protein assemblies in other dis-
eases cannot yet be classified as “prion-like” according to defined structural criteria. In this context, it is impor-
tant that animal models of other neurodegenerative diseases involving propagation and spread of assemblies of 
different proteins including tau, amyloid-β and α-synuclein do not generally result in lethal neurodegeneration, 
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implying that the basic architecture of mammalian prions may be unique and critical to their ability to act as 
lethal pathogens3.
Progress in understanding prion structure has been severely hindered by the difficulty of isolating relatively 
homogeneous prion particles from infected tissue and unequivocally correlating infectivity with composition and 
structure. However, we recently developed new methods for isolating exceptionally pure, high-titre infectious 
prion preparations from mouse brain and showed that pathogenic PrP in these preparations is assembled into 
rod-like assemblies (PrP rods) that faithfully transmit prion strain-specific phenotypes when inoculated into 
mice8. Subsequently, using sensitive cell culture infectivity assays we established that the PrP rods are intrinsically 
infectious and that changing the number of aggregates into which the rods are distributed proportionally changes 
the number of infectious units available to cells at inoculation9. Electron tomography of negatively-stained prion 
rods from multiple prion strains revealed a common three-dimensional architecture comprising a pair of short, 
intertwined fibres, each with a double helical repeating substructure, separated by a distinct gap of 8–10 nm 
in width9. Hierarchical assembly of PrP into a paired fibre structure (20 nm in width) appears to be a key fea-
ture of infectious prions and contrasts markedly with non-infectious amyloid PrP fibrils generated in vitro from 
bacterially-expressed recombinant PrP which consist of only a single fibre (10 nm wide) composed of a double 
helical arrangement of two protofilaments9,10.
Previously we hypothesised that some of the PrP N-linked glycans (present in the ex vivo PrP rods but not in 
recombinant PrP fibrils) may be involved in linking the paired fibres of the PrP rods and might reside predomi-
nantly in the 8–10 nm central gap of the rod9. However, the use of negative stain in our previous studies precluded 
the ability to visualise material in this central region of the rod. Accordingly, in this study we have now examined 
infectious ex vivo PrP rods and non-infectious recombinant PrP fibrils by cryo-electron microscopy (cryo-EM) 
and atomic force microscopy (AFM) using unstained samples. Images collected show that negative stain makes 
little difference to the overall dimensions of these assemblies and confirms their key structural differences. AFM 
imaging and concurrent quantitative measurement of the adhesion interaction with a silicon tip shows unequiv-
ocal evidence for biological material in the central 8–10 nm gap of the infectious PrP rods, which now formally 
excludes the possibility that the paired fibre assembly of the PrP rods is an artefact of staining methods. This 
central material has an irregular topography and adhesive properties that are significantly different to that of the 
outer surface of the paired fibres of the PrP rod, consistent with the idea that N-linked glycans may be fulfill-
ing a key structural role9. The first cryo-EM images of unstained, high titre, ex vivo infectious PrP rods formed 
from wild-type PrP shown here, allied with significant new AFM findings, now defines the configuration of the 
authentic infectious prion assembly state that should be targeted in future high resolution structural studies of 
mammalian prions.
Results
Structural features of non-infectious recombinant PrP fibrils. Non-infectious recombinant mouse 
PrP fibrils generated from bacterially expressed mouse PrP are composed of two intertwined protofilaments with 
a subunit repeat of ~6 nm when imaged in 2D and 3D by negative stain EM and electron tomography9,10. The 
fibrils appear as single fibres that are typically several micrometres long and have a width of ~10 nm (Fig. 1a). 
Here we have examined fibrils formed from full length mouse PrP in their native fully hydrated state by cryo-EM 
(Fig. 1b) and also by AFM after drying onto mica (Figs 1c,d and 2a). By both methods the morphology and the 
dimensions of the fibrils were entirely consistent with the negative stain EM images. In particular, a fibril width 
of ~10 nm was congruent with all three methods (Table 1). AFM provided determination of the height of fibrils 
as 4.0 ± 0.8 nm (Table 1, Figs 1c and 2a), and width:height ratios were consistent across all of the recombinant 
PrP fibrils examined. AFM was also used to concurrently measure the surface topography and corresponding 
adhesion interaction forces between the surface of the fibril and silicon tip. The fibrils were relatively smooth 
(Figs 1c,d, 2a and 3a) but showed variable adhesive force interactions along their length (Fig. 3b) with a perio-
dicity of 7.1 ± 0.8 nm which corresponds well to the 6 nm repeating subunit density seen by negative stain EM9,10. 
To enable accurate comparison between adhesive data collected on different PrP assemblies the adhesive forces 
were normalised as a percentage of the adhesive interaction between the silicon tip and exposed mica in each 
image, as the exposed mica is a common background feature to all samples. All adhesive forces measured were 
below 1 nN (Table 2). For the recombinant PrP fibril the average adhesive interaction was measured to be 66% of 
that measured for mica (Table 2) with the periodic variations along their length being ± 19% about the average.
Structural features of infectious prion rods. In comparison to the relatively simple architecture of 
non-infectious recombinant PrP fibrils, infectious PrP rods isolated ex vivo from multiple rodent-adapted prion 
strains (RML and ME7 prions from mice and Sc237 prions from hamsters8) have a more complex structure9. 
Each PrP rod is composed of a pair of short, intertwined fibres, each with a double helical repeating substruc-
ture, separated by a distinct gap 8–10 nm in width9 (Figs 2b,c, 3c,d and 4a–f). This architecture is apparent when 
rods are imaged by negative stain EM regardless of the type of the stain used (uranyl acetate at pH 4 or NanoW 
at pH 6.8) (Fig. 4a,b) and is clearly observed in 3D by electron tomography9. We now extend our understanding 
of PrP rod structure by imaging unstained RML and ME7 PrP rods in their native, hydrated state by cryo-EM 
and also by AFM after drying onto mica. Importantly, in keeping with our finding that PrP rods when dried 
onto carbon-coated EM grids showed no loss of prion infectivity in cell culture9, PrP rods when dried onto mica 
substrates for AFM were also similarly infectious (Fig. 5). Findings from negative stain EM, cryo-EM and AFM 
therefore all report on the same authentic, biologically active, structure.
Images from both cryo-EM and AFM corresponded closely with images from the earlier negative stain EM 
and confirm the striking difference in the structure between the PrP rods and the single recombinant PrP fibres. 
In vitreous ice, RML PrP rods (Fig. 4c,d) have dimensions closely similar to those measured from negative stain 
EM with a width of 19.4 ± 2.3 nm (mean ± SD; n = 18) and a gap of 8–10 nm separating the paired fibres (Table 1). 
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Repeating structural units at 6.3 ± 0.4 nm along the length of each of the paired fibres were seen by AFM (Fig. 2c) 
which is consistent with observations of repeating structural units in the paired fibres at intervals of 6.5 ± 0.5 nm 
measured from negative stain electron tomography. The overall height of the PrP rod from the mica surface (to 
the highest point of each paired fibre when the rod is lying flat) is 9.2 ± 0.5 nm (Fig. 2b) (Table 1) while the central 
gap region has a reduced height of 7.4 ± 0.8 nm where the rod appears to dip in the centre (Fig. 4e) (Table 1). 
Width:height ratios were consistent across all of the PrP rods examined. Importantly, imaging of RML PrP rods 
by AFM not only clearly defines the central 8–10 nm gap of the rod (Figs 2b,c and 4e,f) but also reveals the pres-
ence of biological material within the central gap which appears to link the paired fibres of the rod (Figs 2b,c and 
4e,f). Notably this central gap material appears to have a more irregular structure along its length (Fig. 2c, dotted 
line) than the repeating structure seen along the length of the fibres of the rod (Fig. 2c, continuous line).
To date the adhesive properties of prion rods have not been explored. Accordingly, to examine this we used a 
silicon AFM tip to measure surface topography and reveal the adhesive properties of the rod (Fig. 4f). The outer 
surfaces of the rods appeared smooth which is consistent with our previous evidence suggesting that the PrP 
N-linked glycans are buried within the structure of the rod9. The average adhesive interaction of the rod fibres was 
about 70% of that of the surrounding mica surface and closely similar to that measured for recombinant PrP fibres 
(Table 2). In sharp contrast we found that the average adhesive force of the irregular structural material in the 
central gap of the rod was about 126% of that of the mica surface (Table 2). The adhesive interaction of material 
in the centre of the PrP rod, as compared to that of mica, is therefore nearly twice that of the rod fibres, strongly 
suggestive of a distinct composition.
Figure 1. Non-infectious recombinant PrP fibrils imaged by negative stain EM, cryo-EM and AFM. (a) EM 
image of fibrils stained with NanoW at pH 6.8. (b) Cryo-EM image of unstained fibrils in vitreous ice. The inset 
shows a magnified image of one fibril. Protein-A gold 10 nm were added to this sample as fiducial markers. (c) 
1 µm × 1 µm scan showing height images obtained by AFM. (d) An enlarged image of one fibril from panel c 
with inset showing repeating structure along the fibril length (denoted by arrows) at 7.1 ± 0.8 nm intervals. Scale 
bars, 100 nm main panels a, b and c, 10 nm, main panel d and inset panel b, 5 nm, inset panel d.
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In a final series of experiments we examined PrP rods from another prion strain (PrP rods purified from the 
brain of C57Bl/6 mice terminally infected with the ME7 prion strain8) by negative stain EM (Fig. 6a,b), cryo-EM 
(Fig. 6c,d) and AFM (Fig. 6e,f). Structural features determined by cryo-EM and AFM were entirely consistent 
with data from our previous analyses of ME7 prion rods by negative stain electron tomography9. The width of the 
ME7 rods measured by negative stain EM (using NanoW) was 20.5 ± 2 nm (mean ± SD; n = 18) compared to a 
width of 18.5 ± 2 nm (mean ± SD; n = 18) measured by cryo-EM, indicating that dehydration and staining have 
little effect on the dimensions of the rods. By AFM the paired fibres of the ME7 rods appeared smooth with no 
apparent protrusion of PrP N-linked glycans from their surface. Importantly, analogous to findings with RML 
prion rods, AFM revealed the presence of material in the central 8–10 nm gap of ME7 PrP rods with an adhesivity 
that was greater than that of the rod fibres (Fig. 6e,f). Findings for ME7 rods by all three methods therefore con-
vincingly demonstrate that their overall architecture is closely similar to that of RML PrP rods.
Figure 2. Non-infectious recombinant PrP fibrils and infectious RML PrP rods imaged with high resolution 
AFM tips. (a–c) Representative 2D surface topography images. (a) Recombinant fibrils have an average width of 
10.4 ± 1.2 nm and an average height of 4.0 ± 0.8 nm. The graph plots height profiles at the positions of the solid 
and dotted lines. (b) RML prion rods have a fibre height of 9.2 ± 0.5 nm and an overall width of 26.5 ± 0.3 nm. 
The height of the central gap material is 7.4 ± 0.8 nm. (c) RML prion rods have repeating structure at 
6.3 ± 0.4 nm intervals along the length of the fibres (solid line) and have material with a more irregular structure 
down the 8–10 nm central gap of the rod (dotted line) that separates the paired fibres. The tip broadening 
artefacts displayed in the raw profiles are removed through deconvolution for the calculation of dimensions 
given above and in Table 1. Scale bars, 10 nm.
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Discussion
In this study, we have examined the architecture of unstained preparations of ex vivo infectious PrP rods and 
non-infectious recombinant PrP fibrils. Our findings with cryo-EM and AFM confirm the key structural differ-
ences that we observed with negatively stained samples by electron tomography9 and exclude the possibility that 
stain distorted these structures or that staining artefacts contribute to their morphology. The basic architectures 
of the two assemblies are strikingly distinct. Infectious PrP rods are ~20 nm wide and are composed of two fibres 
(each with a double helical substructure) separated by a gap of 8–10 nm. AFM of unstained samples reveals that 
this central gap contains irregularly-structured material that appears to be compositionally distinct from the 
surface of the individual fibres. This finding is consistent with a proposed involvement of PrP N-linked glycans 
in linking the paired fibres of the rod9 as the marked protease-resistance of the rods8,9 is difficult to reconcile with 
irregularly structured material if this were comprised solely of protein. In contrast to the structural complexity of 
the PrP rods, non-infectious recombinant PrP fibrils are single fibres ~10 nm wide with a double helical arrange-
ment of two protofilaments.
Based upon our previous findings8,9 and this study, we have defined PrP rods as the target for future high 
resolution studies of authentic prion structure. Recently, Wille and colleagues also sought to investigate mamma-
lian prion structure using cryo-EM11, however to our surprise, the structure they described comprised a single 
PrP fibre ~10 nm wide composed of two protofilaments11 with an overall architecture closely similar to that of 
our non-infectious recombinant PrP fibrils. We consider that this finding is directly attributable to their use 
of prions isolated from the brains of transgenic mice expressing GPI-anchorless PrP (tg44 mice) infected with 
RML prions11. RML prion-infected tg44 mice replicate prions (that can be subsequently titrated in wild-type 
Sample Method
Width mean ± SD 
(nm)
Length mean ± SD
(nm)
Height mean ± SD
(nm)
Recombinant PrP fibrils
Negative stain EM
(n = 18 fibrils) 10.4 ± 1.2 >700 —
Cryo-EM
(n = 18 fibrils) 9.3 ± 0.8 >700 —
AFM
(n = 6 fibrils) 11.3 ± 2.2 >700 4.0 ± 0.8
Ex vivo RML prion rods
Negative stain EM
(n = 18 rods) 20.2 ± 1.9* 127.5 ± 41.3
Cryo EM
(n = 18 rods) 19.4 ± 2.3
§ 118.3 ± 23.8
AFM
(n = 8 rods) 26.5 ± 0.3
# 111.5 ± 17.4 9.2 ± 0.5$
Table 1. Dimensions of non-infectious recombinant PrP fibrils and infectious RML prion rods by EM and 
AFM. *Central gap width 9.1 ± 1.4 nm. §Central gap width 8–10 nm. #Central gap width 8.0 ± 0.9 nm. $Central 
gap height of 7.4 ± 0.8 nm.
Figure 3. 3D-imaging of non-infectious recombinant PrP fibrils and infectious RML PrP rods by AFM. 3D 
surface renderings of (a,b) non-infectious recombinant PrP fibrils and (c,d) infectious RML PrP rods. (b,d) 
show the 3D surface renderings with the adhesive interaction force measured by the cantilever tip overlaid as a 
blue colour-scale (light to dark representing high to low adhesive force). Scale bar, 10 nm.
www.nature.com/scientificreports/
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mice) but they also develop intense PrP amyloid deposits throughout their brain which are not seen in RML 
prion-inoculated wild-type mice12,13. Notably, the GPI-anchor-deficient PrP expressed in these mice is mainly 
non-glycosylated12,13, so that these mice are in effect producing a high level of what is essentially recombinant 
PrP along with a minor population of glycosylated PrP species. Caughey and colleagues have described two mor-
phologically distinct PrP fibril assemblies in prion-infected tg44 mouse brain14–16 and inspection of their images 
shows clear evidence for the presence of paired fibre PrP rods (~20 nm in width) together with other single PrP 
fibres of ~10 nm in width. The PrP fibrils isolated from the brain of RML prion-infected tg44 mice by Wille and 
colleagues showed tight uniformity in width (9.55 ± 1.15 nm; n = 261)11 indicating that their purification proto-
col had resulted in preferential enrichment of these single PrP fibres. Importantly, the specific prion infectivity 
of their purified PrP fibre preparation (with respect to protease-resistant PrP concentration) was dramatically 
reduced compared to the RML prion-infected tg44 mouse brain homogenate used for purification. Using the 
original prion titration data for RML prion-infected tg44 mouse brain reported by Chesebro and colleagues12, 
the mean prion incubation periods of 153 days for RML prion-infected tg44 mouse brain homogenate and 203 
days for purified PrP fibrils observed in C57Bl/6 mice by Wille and colleagues11 would correspond to a 102–103 
fold reduction in infectious prion titre12. Collectively, based upon the published data, we conclude that RML 
prion-infected tg44 mouse brain propagates paired fibre PrP rods (20 nm wide) which account for the transmis-
sible prion infectivity and structurally distinct single PrP fibres (10 nm wide) which account for the abundant 
PrP amyloid plaques that characterise these mice. It appears therefore that Wille and colleagues have structurally 
characterised the far more abundant, single fibre PrP fibrils rather than the infectious PrP rods.
Generation of GPI-anchorless PrP mice has provided significant insight into the pathogenesis of inherited 
forms of human prion disease in which prominent amyloid PrP plaque deposition is a major feature12,13,17,18. 
These include PRNP stop mutations that result in C-terminally truncated GPI-anchorless PrP isoforms and a 
range of PRNP missense point mutations some of which are associated with Gerstmann-Sträussler-Scheinker 
(GSS) disease phenotypes19–22. A common feature of some of these missense point mutations is that the expressed 
full-length mutant PrP forms two distinct disease-associated assemblies of misfolded PrP. One assembly forms 
N-terminally truncated protease-resistant fragments that correspond to those generated from classical PrPSc (PrP 
27–30 see ref.1; analogous to that produced from ex vivo PrP rods8,9) which is enriched in brain areas showing 
synaptic PrP deposition, spongiform vacuolation and neurodegeneration. The other disease-associated assembly 
leads to smaller N- and C-terminally truncated protease-resistant fragments (typically 7–15 kDa, derived from 
the central region of PrP) which is associated with PrP amyloid plaques23–31. These distinct disease-associated PrP 
assembly states from GSS patients with the P102L PrP mutation transmit different phenotypes to experimental 
reporter mice resulting in either a lethal transmissible spongiform encephalopathy (associated with transmission 
of classical PrPSc) or a clinically silent PrP amyloidosis (associated with the transmission of the PrP conformer 
generating an ~8 kDa, protease-resistant PrP fragment)32,33. Based upon the evidence that RML-infected tg44 
mice are propagating PrP rods and structurally distinct single PrP fibres, it seems probable that both PrP rods and 
distinct single fibre PrP assemblies might also be propagating in some inherited prion diseases. Variation in the 
substructure of PrP rods or the single PrP fibrils (governed by the specific PrP missense mutation) may dictate 
their strain-specific transmission properties and host range via conformational selection2,3,34,35, while temporal 
and spatial differences in their accumulation (either predominantly PrP rods or single PrP fibrils within particular 
brain regions) might underlie the diverse clinicopathological phenotypes that are seen in family members with 
the same PRNP mutation19,21,22,36. Although the work of Wille and colleagues11 does not report the structure of 
infectious PrP rods, the architecture of an ex vivo single PrP fibril is nevertheless of major interest as the propaga-
tion of single fibrils may significantly influence clinical and pathological disease phenotypes in humans.
In summary, the structure of infectious PrP rods that we describe here readily distinguishes them from the 
available characterised structures of tau, amyloid-β and α-synuclein that propagate in other neurodegenerative 
diseases5–7 and from numerous other PrP aggregates proposed by others as infectious prion assembly states (for 
reviews see refs 37,38). Our finding that the characteristic 8–10 nm gap between the paired fibres of infectious PrP 
rods contains material with an irregular topography that is likely to be compositionally distinct to the protein 
surface of the outer fibres is consistent with our proposal that some of the PrP N-linked glycans are located in the 
gap and are contributing to the stability of the assembly, and as a consequence its infectivity9.
Sample
Adhesion Force Interaction (nN) Mean ± SD
Mica Surface Fibre surface Central gap
RML prion rods 0.69 ± 0.07(n = 90)
0.49 ± 0.11
(n = 8 rods; 242 total 
measurements)*,†
0.87 ± 0.08
(n = 8 rods; 105 total 
measurements)*,†
Recombinant PrP fibrils 0.82 ± 0.11(n = 160)
0.54 ± 0.16
(n = 6 fibrils; 183 total 
measurements)*
N/A
Table 2. Adhesion force interaction measurements of RML prion rods and recombinant PrP fibrils using AFM. 
*Means were generated from multiple measurements (>10) made along the length of each individual object (8 
RML PrP rods or 6 recombinant PrP fibrils). †Difference in the mean values between the fibre surface and the 
central gap of the RML rods is statistically significant (p < 0.0001, unpaired t test with Welch correction). N/A, 
not applicable.
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Methods
Research governance. Frozen brains from mice with clinical prion disease were used to generate purified 
prion samples. These brain samples were generated by us as part of a previous study8 in which work with animals 
was performed in accordance with licences approved and granted by the UK Home Office (Project Licences 
Figure 4. Infectious RML prion rods imaged by negative stain EM, cryo-EM and AFM. (a,b) Negative stain EM 
images using (a) uranyl acetate at pH 4 and (b) NanoW at pH 6.8. (c,d) Cryo-EM images. (e) 140 nm × 140 nm 
AFM scan revealing the presence of material in the central gap of the rod which appears to link the paired fibres. 
Main panel 3D image, inset, 2D image. (f) AFM surface topography (height) adhesion force mode showing 
that material in the central gap region of the rod interacts more strongly with the scanning tip (exerts a greater 
adhesive force) than the rod fibres (light to dark representing high to low adhesive force). Scale bars, 100 nm 
main panels a, b and d, 200 nm panel c, 10 nm main panels e and f and insets in panels a and e.
www.nature.com/scientificreports/
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70/6454 and 70/7274) and conformed to University College London institutional and ARRIVE guidelines. All 
experimental protocols were approved by the Local Research Ethics Committee of UCL Institute of Neurology/
National Hospital for Neurology and Neurosurgery. Prion purification and cell based prion bioassay was con-
ducted at UCL in microbiological containment level 3 or level 2 facilities with strict adherence to safety protocols. 
Work with infectious prion samples at Bristol University and Birkbeck College London was performed using ded-
icated sample holders and equipment with strict adherence to safety protocols. Prion samples were transported 
between laboratories in packaging conforming to UN 3373 Biological Substance, Category B specifications.
Purified prions. Prions were purified from 10% (w/v) brain homogenates from terminally affected CD1 mice 
propagating the RML prion strain (isolate I6200) and terminally affected C57Bl/6 mice propagating the ME7 
prion strain (isolate I14050) as described previously8,9. Brain homogenates (10% (w/v)) from uninfected CD1 
mice (isolates I10340 or I14040) were used to generate control samples. Full details of the purification method 
have been described and we used purified P4 fractions prepared without proteinase K digestion for all experi-
ments8. The method produces a recovery of ~10% of the prions present in the starting 10% (w/v) brain homoge-
nate so that resuspension of the purified P4 pellet fraction in buffer at one tenth of the volume of the 10% (w/v) 
brain homogenate from which it was derived produces prion preparations whose infectivity titre matches that 
Figure 5. Measuring the infectivity of RML prion rods bound to mica supports for AFM. (a) Schematic 
diagram showing how prion infectivity of purified RML PrP rods was measured in cell culture. Identical 
aliquots of purified RML prion rods were either applied to cells as solution or dried onto sections of mica before 
application of cells. Infectivity was measured using methods based upon the Scrapie Cell Assay45. (b) Levels 
of infectivity (spot count) plotted against the concentration of purified RML prion rods (0.001–1x relative 
concentration range) after drying onto mica (green) or applied to cells in-solution (red). Data points show mean 
spot count ± SEM n = 18; 3 independent experiments using three different preparations of purified RML PrP 
rods. 1x relative concentration of RML prion rods in this experiment corresponds to about 2,500 intracerebral 
LD50 units in Tg20 mice. Recombinant PrP fibrils or purified P4 fractions from normal mouse brain showed no 
detectable prion infectivity when applied either in-solution or after drying onto mica.
www.nature.com/scientificreports/
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of the starting 10% (w/v) brain homogenate8. RML isolate I6200 has a prion titre of 107.3 ± 0.5 (mean ± SD; n = 6) 
intracerebral LD50 units/ml when end-point titrated in Tg20 mice8. Concentration of purified prions or buffer 
exchange was achieved by centrifugation at 16,100 g for 30 min and resuspension of the pellet fraction into the 
desired volume and buffer of choice. Routine SDS-PAGE, silver staining and PrP immunoblotting to characterise 
purified prion preparations was performed using published procedures8,39.
Figure 6. Infectious ME7 prion rods imaged by negative stain EM, cryo-EM and AFM. (a,b) Negative stain 
EM using (a) uranyl acetate at pH 4 and (b) NanoW at pH 6.8. (c,d) cryo-EM images in vitreous ice. (e,f) AFM 
scanning with high resolution tips, (e) height mode and (f) surface topography (height) adhesion force mode 
scanning. The adhesive force interaction of material in the central gap of the two ME7 PrP rods shown was 
about 1.6 times greater than that of the rod fibres. Scale bars, 100 nm panels a,b,d–f, 200 nm panel c, 10 nm inset 
in panel b.
www.nature.com/scientificreports/
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Recombinant PrP fibrils. Recombinant mouse PrP (Prnp allele a; amino acid residues 23–231) was purified 
from E. coli BL21(DE3) and folded in to a β-sheet rich conformation (β-PrP) in 10 mM sodium acetate/10 mM 
tris-acetate buffer pH 4 containing 1 mM DTT as previously described9,10,40. Samples were subsequently adjusted 
with 1 M HCl to pH 3 and a final protein concentration of 0.5 mg/ml in 10 mM sodium acetate/10 mM tris-acetate 
buffer, after which 100 µl aliquots were incubated for three to five months without agitation at 25 °C in sealed 
1.5 ml tubes. Recombinant PrP fibrils were harvested by centrifugation at 13,000 g for 45 min after which pellets 
were resuspended in 100 µl of 10 mM sodium acetate/10 mM tris-acetate buffer pH 3.0. These stocks were stored 
at 25 °C.
Negative stain electron microscopy. Full methods used have been published previously9. Briefly sam-
ples were loaded onto carbon-coated 300 mesh copper grids (Electron microscopy Sciences) that were glow dis-
charged for 40 seconds using an PELCO easiGLOW™ glow discharge unit (Ted Pella Inc, USA). Samples were 
left to bind for 2 minutes, blotted, washed briefly in one water drop, blotted, and then stained with either NanoW 
stain (Nanoprobes) 2 × 1 min or 2% (w/v) uranyl acetate in water for 45 sec, then blotted and air-dried. Grids 
were inserted into the microscope using a dedicated sample holder for mouse prions with strict adherence to risk 
assessment and microbiological containment level 2 safe working practice. The sample holder was decontami-
nated directly after use by exposing to plasma using a Fischione 1020 plasma cleaner. Images were acquired on 
an FEI Tecnai T10 electron microscope (FEI, Eindhoven, NL) operating at 100 kV and recorded on a 1 k × 1 k 
charged couple device (CCD) camera (Gatan) at a nominal magnification of 44,000 with a pixel size of 3.96 Å. 
Fibril dimensions were measured in ImageJ41 and IMOD42. Because of their helical twist, prion rods and recom-
binant PrP fibrils viewed on a surface alternate between wider, face-on and narrower, edge-on views of the struc-
ture. The dimensions reported here were measured on the widest parts of the fibrils.
Cryo-electron microscopy. We examined purified prion rods (typically resuspended in 1/100 of the vol-
ume of 10% (w/v) brain homogenate from which they were derived) and recombinant PrP fibrils (stock prepara-
tions diluted 5-fold in 10 mM sodium acetate/10 mM tris-acetate buffer pH 3.0). Protein samples were sonicated 
for 20 sec in a Sonicator 3000 (Misonix) at 40 W at 4 °C and then mixed with Protein A-10 nm gold solution 
(Electron Microscopy Sciences) (pre-sonicated for 5 sec as above) at a ratio of 1:25 (v/v). 3 µl of sample was loaded 
onto carbon-coated 300 mesh copper or gold grids (Electron Microscopy Sciences) that had been glow discharged 
for 1 min using a PELCO easiGLOW™ glow discharge unit (Ted Pella Inc, USA) and allowed to bind for 1.5 min. 
Grids were then blotted for 4–7 sec prior to freezing in liquid ethane using a manual plunging device after which 
the grids were stored in liquid nitrogen. Samples were imaged using a dedicated Gatan cryo-transfer holder 
(model 626) on an FEI Tecnai T12 electron microscope (FEI, Eindhoven, NL) operating at 120 kV and recorded 
using a US4000 CCD camera (Gatan) typically using 1 to 3 µm defocus and a nominal magnification of 42,000 
with a pixel size of 4.1 Å. After use, the holder was decontaminated using a Fischione 1020 plasma cleaner. Fibril 
dimensions were measured in ImageJ41 and IMOD42. Fibril and rod dimensions were measured on the widest 
regions of the fibrils, as for the negative stain EM.
Atomic force microscopy. Prior to loading onto mica, purified prions (typically resuspended in 1/25 of 
the volume of 10% (w/v) brain homogenate from which they were derived) and recombinant PrP fibril sam-
ples (0.5 mg ml−1 protein) were washed once with water to reduce the concentration of contaminating salts and 
detergents. This was done by resuspending 40 µl of each sample in 500 µl of ultrapure water and centrifugation 
at 16,100 g for 30 min after which the supernatant was discarded and the bottom of the tube containing the 
sample resuspended in 40 µl ultrapure water. Samples were then sonicated briefly for 10 sec using a Sonicator 
3000 (Misonix) at 40 W at 4 °C after which 1 µl of sample was dispensed onto a freshly cleaved mica surface and 
air-dried. Samples were investigated at room temperature using a Multi-mode VIII microscope with Nanoscope 
V controller and utilising a non-resonant, PeakForce feedback mechanism. In addition, a fast scanning head 
unit was employed with SCANASYST-AIR-HR cantilevers (Bruker) with nominal spring constant, k of 0.4 N/m 
and nominal tip radius 2 nm for imaging large areas (up to 50 µm × 50 µm) in order to identify candidates for 
high resolution investigation. SCANASYST-FLUID+ cantilevers (Bruker) with a nominal spring constant, k of 
0.7 N/m and nominal tip radius <2 nm were used for high resolution imaging of individual PrP rods or recom-
binant PrP fibrils and also for mapping of adhesion interactions across the surface of each. Adhesion interaction 
forces were extracted in real-time from the force curves collected as part of the PeakForce control mechanism. 
Whilst the cantilever type was kept constant between samples, fresh cantilevers were used for each to ensure the 
highest possible topographic resolution was obtained. When comparing adhesion interaction forces for different 
samples it was therefore necessary to negate possible influences of small differences in tip radius through nor-
malising to that of the mica background consistent across all samples43,44. Data was analysed using Nanoscope 
Analysis software (Bruker). Dimensions reported by AFM in Table 1 were determined from 8 RML prion rods 
or 6 recombinant PrP fibrils. Both assemblies vary in height and width according to their helical twist, and the 
dimensions reported in Table 1 were determined from the widest regions, as for the EM. Adhesion force inter-
action measurements were similarly determined from 8 RML prion rods or 6 recombinant PrP fibrils taking 
multiple measurements along their length as reported in Table 2. Statistical analyses of mean adhesion force 
interaction values were performed using Graphpad Instat software with p values calculated using an unpaired t 
test with Welch correction.
Mica-bound prion infectivity assay. To measure RML prion infectivity bound to mica, samples of mica 
(Agar Scientific) were cut into 0.5 cm2 pieces and their surface freshly cleaved using Scotch Magic Tape. 1 µl ali-
quots of sample, either recombinant PrP fibrils at protein concentrations of 0.5, 0.05, 0.005 and 0.0005 mg ml−1, 
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or purified RML prions (initially resuspended in a volume equivalent to that of the starting 10% (w/v) brain 
homogenate from which they were derived and 10-fold serial dilutions thereof), were applied to the mica surface 
and air-dried. Mica sections were then placed in the bottom of the wells of tissue culture plates (Nunc 12-well 
× 2 ml polystyrene multidish, Capitol Scientific) followed by the addition of 2.5 ml of PK1/11 cell suspension (80 
cells µl−1) in OFCS (OptiMEM, 10% FCS, penicillin and streptomycin) to give a total of 200,000 cells per well. 
In parallel, replicate tissue culture plates were prepared in which 1 µl of each purified prion or recombinant PrP 
sample was applied as solution to wells containing PK1/11 cells (as above). For both conditions cells were then 
incubated for 3 days. Cells growing on mica were harvested by transferring each mica section to a well of a new 
tissue culture plate followed by washing with 2 × 500 µl OFCS medium to remove cells from the mica surface, 
after which the wash fractions were pooled. Cells from the replica plates in which samples had been applied as 
solution were thoroughly resuspended in 1 ml OFCS medium. All recovered cell suspensions were then adjusted 
to a density of 16 cells µl−1 with OFCS media and 250 µl aliquots (4000 cells) transferred to 6 wells of a new 96 
well tissue culture plate (96 Well Clear Flat Bottom Polystyrene TC-Treated Microplate, Corning) and grown to 
confluence for 7 days. Subsequently cells were split at a 1:8 dilution into fresh OFCS media and grown to conflu-
ence for three days and then passaged in a standard Scrapie Cell Assay format (three successive cycles of 1:8 splits 
with three days incubation between splits) before transferring aliquots of the cells to ELISPOT plates for analysis 
of the number of cells containing proteinase K-resistant PrP “spot count”8,45,46. As a negative control, purified P4 
samples from non-infected CD1 mouse brain were analysed in an identical fashion. We analysed three different 
purified P4 preparations from RML-infected CD1 mouse brain using these methods and in each case the prion 
titre of the P4 samples (as determined using the standard Scrapie Cell Assay8,46) was entirely consistent with our 
published findings8. Preliminary experiments in which freshly cleaved blank mica sections were incubated with 
PK1/11 cells showed no deleterious effects on cell health or viability.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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